Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Two Doses of PF-03654746 in Adults With Attention Deficit Hyperactivity Disorder (ADHD). [Phase 2]

View source ↗

Summary

Phase 2 study evaluating two doses of PF-03654746 for attention deficit hyperactivity disorder in adults completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• PF-03654746

Snippet

Sponsor: Pfizer | Conditions: Attention Deficit Hyperactivity Disorder | Phase 2 | Status: COMPLETED | Results posted: 2016-02-19